Last reviewed · How we verify

Etoricoxib 90 mg

Organon and Co · FDA-approved active Small molecule Quality 5/100

Etoricoxib 90 mg is a Small molecule drug developed by Organon and Co. It is currently FDA-approved. Also known as: MK-0663, Etoricoxib, There is no other intervention name.

At a glance

Generic nameEtoricoxib 90 mg
Also known asMK-0663, Etoricoxib, There is no other intervention name
SponsorOrganon and Co
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Etoricoxib 90 mg

What is Etoricoxib 90 mg?

Etoricoxib 90 mg is a Small molecule drug developed by Organon and Co.

Who makes Etoricoxib 90 mg?

Etoricoxib 90 mg is developed and marketed by Organon and Co (see full Organon and Co pipeline at /company/organon-and-co).

Is Etoricoxib 90 mg also known as anything else?

Etoricoxib 90 mg is also known as MK-0663, Etoricoxib, There is no other intervention name.

What development phase is Etoricoxib 90 mg in?

Etoricoxib 90 mg is FDA-approved (marketed).

Related